The recent possibility of undertaking a treatment-free remission (TFR) approach in patients with a stable DMR has underlined the importance of reliable and precise monitoring of BCR–ABL1 molecular levels in CML patients treated with TKIs. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.